Equities research analysts forecast that Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) will announce earnings per share (EPS) of $0.34 for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Sucampo Pharmaceuticals’ earnings. The lowest EPS estimate is $0.32 and the highest is $0.36. Sucampo Pharmaceuticals posted earnings of $0.68 per share in the same quarter last year, which would suggest a negative year over year growth rate of 50%. The firm is expected to report its next earnings report on Wednesday, March 14th.

According to Zacks, analysts expect that Sucampo Pharmaceuticals will report full-year earnings of $1.12 per share for the current year, with EPS estimates ranging from $1.09 to $1.14. For the next financial year, analysts forecast that the firm will report earnings of $1.19 per share, with EPS estimates ranging from $1.05 to $1.36. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Sucampo Pharmaceuticals.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.02. The company had revenue of $61.27 million for the quarter, compared to analyst estimates of $58.05 million. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The firm’s revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.30 EPS.

Several equities research analysts recently commented on SCMP shares. Maxim Group set a $23.00 target price on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. TheStreet downgraded shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research report on Wednesday, August 2nd. Roth Capital set a $30.00 target price on shares of Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. BidaskClub downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 5th. Finally, Leerink Swann started coverage on shares of Sucampo Pharmaceuticals in a research report on Monday, August 21st. They set an “outperform” rating and a $15.00 target price on the stock. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $16.00.

In other news, major shareholder Sachiko Kuno sold 1,000,000 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $12.00, for a total value of $12,000,000.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jason Patrick Meyenburg purchased 4,000 shares of the company’s stock in a transaction dated Wednesday, September 6th. The stock was purchased at an average price of $12.13 per share, for a total transaction of $48,520.00. Following the transaction, the insider now directly owns 30,228 shares in the company, valued at approximately $366,665.64. The disclosure for this purchase can be found here. 4.13% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the stock. HPM Partners LLC acquired a new position in shares of Sucampo Pharmaceuticals during the 2nd quarter valued at $1,307,000. Louisiana State Employees Retirement System lifted its position in shares of Sucampo Pharmaceuticals by 1.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 100 shares during the period. Trexquant Investment LP acquired a new position in shares of Sucampo Pharmaceuticals during the 3rd quarter valued at $122,000. Nine Chapters Capital Management LLC acquired a new position in shares of Sucampo Pharmaceuticals during the 3rd quarter valued at $127,000. Finally, First Citizens Bank & Trust Co. acquired a new position in shares of Sucampo Pharmaceuticals during the 2nd quarter valued at $116,000. Institutional investors own 57.79% of the company’s stock.

Shares of Sucampo Pharmaceuticals (SCMP) opened at $10.55 on Friday. The company has a current ratio of 5.11, a quick ratio of 4.46 and a debt-to-equity ratio of 7.37. Sucampo Pharmaceuticals has a 1 year low of $9.30 and a 1 year high of $17.55. The company has a market cap of $485.01, a P/E ratio of 7.12, a P/E/G ratio of 3.10 and a beta of 1.38.

COPYRIGHT VIOLATION WARNING: “Analysts Anticipate Sucampo Pharmaceuticals, Inc. (SCMP) to Announce $0.34 EPS” was first published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/analysts-anticipate-sucampo-pharmaceuticals-inc-scmp-to-announce-0-34-eps/1724844.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Get a free copy of the Zacks research report on Sucampo Pharmaceuticals (SCMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.